European Journal of Molecular & Clinical Medicine

ISSN 2515-8260 Volume 09, Issue 07, 2022

Original Research Article

Update And Challenges Of Pellets

Swagatika Das[1]*, Manmayee Mohapatra[2], Sidhartha Parida[3], Debasish Karan[4], Souvik Giri[5], Archana Pattanaik[6]

[1]*, [3]Centurion University of Technology and Management, Odisha, India,

[2]Gayatri Institute of Science and Technology, Gunupur

[4]Hi-Tech College of Pharmacy, Bhubaneswar, Odisha, India.

[5,6] Sri Jaydev College of Pharmaceutical Science, Naharkanta, Bhubanesar

***Corresponding Author:** Miss Swagatika Das

*Asst. Professor, Centurion University of Technology and Management, Odisha, India.
Email Id: swagatikadas.med@gmail.com, Contact No- 9337169903

ABSTRACT:

The goal of this artwork is to discover and compile the most common, everyday problems that happen during pellet production. Significant difficulties in recognising aspects starting with raw cloth homes and continuing through the pelletization's final drying process. On this evaluation, the difficult problems relating to the physical and chemical properties, interactions between drugs and excipients, and the effects of raw material type, grade, and quantity on pellet properties are covered. The emphasis is also placed on technological and process-related challenging conditions in the common used pelletization ideas, as well as extrusion-spheronization, warm-soften extrusion, and stacking processes. The research also provides insight into practical methods for addressing pellets' exceptionalities at various stages of development.

INTRODUCTION;

Particles that are small, free-flowing, spherical or semi-spherical in shape and used as a multipartuculate dosage form in the pharmaceutical industry are known as pellets. Pellets are made by combining finely ground pharmaceutical ingredients with excipients to create agglomerations. The pelletized drug shipping is getting paramount significance in therapeutics due to their small range of particle length, pelletized medication shipment is becoming increasingly important in therapeutics and preventing dose dumping.[1,2] The creation and adaptable of these drug carriage have opened up entirely new possibilities thanks to technological innovation. Numerous studies have been conducted to improve these formulations while managing the delivery of polymers and procedure parameters to produce high-quality pellets.[3,4] The schematic picture in figure provides an overview of drug delivery programmes, which may be important in terms of choosing a polymer and a production process. Among the various pelletization techniques used are extrusion-spheronization, warm-melt extrusion, layering processes, balling (round agglomeration), compression, globulation, spray drying, spray congealing, and cryopelletization.[5,6,7]



ISSN 2515-8260 Volume 09, Issue 07, 2022

It may be crucial to first examine and evaluated the physicochemical features of the raw material. The drug-excipients may be again entirely by virtue of their inherent qualities; they can be dissolved or undisclosed inside the final dose form. The manufacturing processes that have a substantial impact on the product's stability may be the cause of the drug's current status in dosage form.[8,9]

Effect of particle size and form on method and product:-

The initial material's particle size, as well as capsules, polymers, and binders, have an impact on the pellets' surface roughness. Small debris is widely distributed and creates fewer peaks and valleys.[10,11] Therefore, the bottom of the pellets is smoother the shorter the particle length. Microcrystalline cellulose (MCC) is a beginning material that generates pellets that are smoother than those made with lactose or crosspovidone. It happens as a result of MCC disintegrating into smaller pieces during the soaking procedure. Consequently, the disaggregated particles' particle length determines the floor roughness of the pellet. In addition to MCC, the production of gel after pellet shrinkage can be linked to the smoothness of the pellets.[12,13]

Effect of API assets on processing:

The select of pelletization procedure, as listed in paragraph 1, is greatly influenced by the important fabric properties.[14] Due to the powder mass's awful wet ability, powder with high concentrations of hydrophobic pills is challenging to extrude and spheronize. Due to their low water concentration and slower rate of disintegration, hydrophobic tablets give the pellets actual tensile energy. Hydrophilic medications, on the other hand, demonstrate uniform wet ability of the powder mass. Because they are aware of high tide, they usually congregate. Hydrophilic drug pellet production results in pellets with reduced tensile strength and a higher dissolving rate. When compared to pellets of solubility-boosting medications, pellets of low-solubility pharmaceuticals have a narrower size of dispersion.[15,16,17]



Water content throughout processing:-

The main component that affect size of pellet, radius of length, and form is water content. As the substance with a high water content grows, the pellet size also grows. The amount of water depends on the medicine kind. The pellets created by any such less wetted mass aren't spherical because at high water attention, pellets of powder masses, particularly with hydrophilic medicines, aggregate during spheronization and no longer impart enough plastic residences. With a rise in public awareness of water, the majority and tapped densities as well as the drift price will rise [18,19,20]. Therefore, it's essential to use your best water awareness to obtain pellets that are the right length, spherical, and lesser length variety. A study examined .According to a study, adding Glyceryl monostearate (GMS) to the powder mass may be beneficial for medications that are sensitive to

ISSN 2515-8260 Volume 09, Issue 07, 2022

moisture or the heat energy needed to evaportateH2O because GMS reduces water awareness in the process.[21] Additionally, GMS gave most formulations a smoother floor and significantly less porosity. However, as GMS awareness grows throughout the extrusion and spheronization process, the time of the extrudates and continuously the pellet size will rise [22,23]. Basically, the anhydrous melt extrusion significance has proven to be effective and the most popular one for hydrolisable capsules since it prevents latent drug degradationoccured by hydrolysable capsule.[24]

The floor roughness of the pellets is influenced by the initial material's particle size, which includes binders, polymers, and medicines. Smaller particles are correctly distributed and leave fewer peaks and valleys. Consequently, the floor of the pellets is smoother the smaller the length of the trash. Microcrystalline cellulose (MCC), one of the starting components, produces pellets with smoother surfaces than those made from crosspovidone or lactose.[25,26] this is as a result of MCC breaking down into tiny pieces during the wetting procedure. As a result, the size of the particle of disaggregated particles affects the floor roughness of the pellet. In addition to MCC, the production of gel after pellet shrinkage will also be blamed for the pellets' smoothness.[27,28]

Effect of binders on processibility during extrusion spheronization:

The physical effect and appearance of the pellets are influenced by both the binder's attention and the type of binder’s. Because the binder concentration is more during the spheronization process, pellets with a more length and reduced sphericity are acquired. Due to the fact that when the binder concentration is too high, the little debris might combine with the larger debris to generate even larger debris.[29,30,31]

When compared to other binders such as Methocel E15 LV, Methocel A4M, and HPC-L, some binders, such as HPC-M, have lower effects on particle size and sphericity at increasing concentrations. It was possible to achieve more spherical pellets, a narrow size distribution, and excellent flow by increasing the HPC-M concentration.[32,33]



Figure 1

Effect of Polymer characteristics that are widely exploited during extrusion spheronization:

When choosing a polymer, consideration should be given to the thermoplastic behaviour of the system and the polymer.[34] The plasticizer-polymer aggregate's compatibility and balance are crucial. Triacetin, citrate esters, and occasionally low molecular weight polyethylene glycols are the most often utilised plasticizers. The kind and level of plasticizer impacts how

ISSN 2515-8260 Volume 09, Issue 07, 2022

muchglass transition (Tg) reduction happens for a certain polymer, enhancing the stability of the AP I and polymer. Large molecular polymers may be processed very readily by reducing shear forces. Different factors in plasticizer selection, such as thermostability and plasticizer volatility, are made possible by the reduction of those shear forces.[35,36,37]

METHODS OF CHALLENGES:-

Spheronization, suspension, solution, and powder stacking procedures are the pelletization techniques that are most frequently studied. Another pelletization method gaining importance is hot soften extrusion. The following discusses the issues with those tactics.[38]

1. Method related challenges in extrusion – spheronization process:-

The common pelletization technique is extrusion-spheronization because it produces good quality pellets at a convenient cost. It's a 3-step process overall: 3. Spheronization, 2. Extrusion, and 1. wet Massing. These three stages have a number of essential characteristics that have a great impact on pellet properties. These variables include the type of medication and other excipients (as previously addressed), the type of extruder, the extrusion stress and velocity, and the velocity, stress, and time of spheronization.[39,40,41]

K. Thomas looked into the effects that various extruder types have on spherical characteristics and extrusion behaviour. The extrudates from three different types of extruders were found to have distinctive features in their habitats. The particle size and other extrudate properties were affected by these differences inside the extrudates.[42,43]

Top-rated degree, and then there is barely any variation in the roundness. Along with the spheronization duration, the friction plate's rotational speed also had an effect on the morphologies of the pellets. However, the slower rate of spheronization time increase imparts more attribution pressure than a decrease in spheronization time at a faster speed, which results in more round pellets and more flowable pellets.[44,45,46]

2. Process-related difficulties with the hot melt extrusion method:

Warm metal extrusion provides definite advantages over traditional pelletization techniques, including quicker processing times, no need for solvents, and improved medication distribution. It's still a challenging strategy, though, because of some drawbacks.[47] These include the disintegration of thermolabile capsules, the need for raw materials with good flow properties, the lack of substitutes for heat-solid polymers, and the high energy consumption. These obstacles raise manufacturing costs generally.[48]

To get the optimum processing outcomes, a temperature that is higher than the melting point of semi-crystalline polymers or higher than the glass transition temperature Tg of amorphous polymers but lower than the melting point of crystalline API may be employed.[49]

Claim that the most important factor in spheronization of stable lipid-based completely extrudates is fabric control, which can be achieved by lowering the temperature of the wall jacket. And using an IR light as an external heat source. In comparison to the conventional regularly utilised arrangement, the material's new exposure region to the heat source is quite modest.[50]

3. Method related challenges in layering techniques:

High drug potency and controllable launch pellets are made using temperature suspension stacking and dry powder layering techniques. These methods frequently provide difficulties, such as an increase in pellet size, difficult pellet floor because to the coating ingredients' long particle lengths,

and nozzle blockage leading to uneven layering. The irrelevant type or attention of the binder will cause the floor of the pellets to become permeable. The surface of the pellet will smooth out as the binder concentration rises, but the efficacy will decline. Other elements that affect pellet characteristics include the weight of the centre pellet, the cost of applying the solution, suspension, or powder, the kind, function, and velocity of the atomizer, the temperature, the level of atomization, and the air cap.[51,52,53]

CHALLENGES RELATED TO DRYING PROCESS:

The drying process has a substantial impact on the mechanical strength, surface characteristics, and drug release profile of prepared pellets, according to research. Despite having stronger crushing strength and greater diametrical strength, pellets dried on a tray drier are less elastic. The tray-dried pellets' in-vitro medication release is improved by the lengthy drying time applied by the tray drier. Long drying times, however, affect the pellets' surface smoothness and even have been shown to cause medication degradation.[54,55] On the other hand, drying pellets on a fluidized bed drier takes less time than drying them on a tray, which eliminates the risk of drug thermal degradation. Pellets dried in a fluidized bed dryer have a smoother surface and are more elastic. unlike pellets that were dried on a tray drier. These pellets, however, have lower mechanical strength and slow rates of dissolution. The particle size is also impacted by the drying temperature. Scientists suggested that when temperature rises, pellets tend to contract, resulting in lower particle size.[56,57]

RELEASE MODIFICATIONS FOR DIFFERENT APPLICATIONS:-

1. Improve poorly water soluble medication solubility and dissolution:

The solubility rate of 17-Estradiol hemihydrate (10% w/w) has been observed to increase 30 times when combined with Sucroester WE 15 or Gelucire 44/14 as additives, PEG 6000, polyvinylpyrrolidone, or a vinylpyrrolidone vinyl acetate-copolymer, as compared to pure medicine.[58] The increase in carbamazepine's solubility was noted utilising d-gluconolactone (GNL) in warm melt extrusion. In only 5 minutes, more than 85% of the medicine was launched thanks to the robust dispersion created with Eudragit EPO and hot-soften extrusion (HME) in the drug: carrier ratio of 4:1.[59] Using polyethylene glycol 4000, warm melt carbamazepine extrudes were compared to simple physical aggregates for growth in solubility and dissolution (PEG 4000)as a sometimes melting binder and hydrophilic carrier. When compared to the body combination, the extrudates with consistent form and density showed much speedier release as a sometimes melting binder and hydrophilic carrier. When compared to the body combination, the extrudates with consistent form and density showed much speedier release. Strong curcumin dispersions made with an unusual amount of Poloxamer 407 and a softening method eventually were spheronized after extrusion. It's important to note that while the solubilization of the finished pellets increased, the stable dispersion's solubilization was unaffected by the pelletization procedure. Additionally, the formulation of the pellets had no bearing on the drug launch profile. [60,61,62]

2. Sustained/controlled release/enteric release dosage form

Extrusion spheronization or hot melt extrusion can be used to create matrix-type enteric or sustained release pellets, whereas reservoir-type pellets have a drug core contained in a polymer layer. Utilizing a twin-screw extruder, Nakamichi and thought to be crucial factors. The pellets were kept in the stomach for a very long time as a discreet floating debris-freeing medication for 24 hours. Ethyl cellulose and cellulose acetate were used to create the sustained release gastro-retentive floating pellets of Diltiazem hydrochloride, butyrate (CAB), poly (ethylene-co-vinyl acetate) (EVAC), and polymethacrylate spinoff were placed into tablets by Follonier et al (Eudragit RSPM). Particle length, drug/polymer ratio, and polymer type all had an impact on how much diltiazem hydrochloride discharged.[63] The formulations' release rates were changed by including

croscarmellose sodium (Ac-Di-Sol) and sodium starch glycolate. Pellets with a smooth surface and occasional porosity were created using plasticizers triacetin and diethyl phthalate. The effectiveness of the enhanced hydroxypropyl methylcellulose acetate succinate with nicardipine hydrochloride sustained release pellets. The screw element position and barrel temperature were adjusted to produce a puffed mass with diminishing density that behaves like it's floating sustained launch pill showed just a slight difference when compared to the pellets structured using less expensive excipients.[64,65]

In 2009, Kleinebudde and Reitz developed solvent-free spheronization to produce enhanced sustained release matrix spheres. Dynasan is a binary lipid mixture that contains just Witocan 42/44 in specified proportions To provide extrudates, drugs like 114 and theophylline have been employed as versions.[66] The development of circular sustained launch matrix pellets with a small particle size distribution, specified floor area, and low porosity was made possible by maintaining low product temperature and managing jacket temperature appropriately. By employing warm soften extrusion, various wax polymers were explored to give a controlled launch dosage form After processing diclofenac as a representative drug and carnauba wax, it was observed that a wax matrix with high mechanical power could be produced even at temperatures below the melting point of the wax.[67,68] The amount of sodium chloride, hydroxypropyl cellulose, and methacrylic acid copolymer (Eudragit L-100) used in the granule formulation had a significant impact on the dissolving release. Some of the most attractive study subjects for experts in controlled release dose forms are low processing temperatures, high kneading and dispersing potential, and low house time of the fabric in an extruder. Polyethylene vinyl acetate (EVA) copolymer-based launch reservoir configurations, for example, were better handled by researchers.[69] with the aid of soften extrusion generation, which appropriately causes Implanon and Nuvaring era. A controlled release of olanzapine over the course of 24 hours was achieved by combining SLS as the pore-forming substance with Glyceryl Palmito-Stearate, microcrystalline cellulose, Sodium Alginate, and the drug (20: 55: 05: 20% w/w).[70,71] The observation shows that a modest concentration of surfactants in a mixture of lipid and MCC can successfully control the release rate from delivery devices. The extrusion/spheronization procedure was used to combine Eudragit and microcrystalline cellulose (Avicel PH 100 and 1) to create lined Ketorolac pellets. Release in an acidic medium was less than 10%, whereas with an improved formulation, it was completed in 60–120 minutes in phosphate buffer (pH 6.8).The nanocrystalline ketoprofen was made into pellets to regulate the medicine's release. Ketoprofen's rate of release increased, however because maize starch was utilised to make the pellets, the procedure of restoring the drug was more difficult.[72,73] Cremophor RH 40 was consequently added continuously during the pelletization process, resulting in sustained launch. The modified release pellets of apremilast were created by Nandgude et al using microcrystalline cellulose (MCC), lactose, TKP, and cross polyvinnile ability to sustain the discharge for up to five. [74] By using ethyl cellulose coating in the Wurster coater to modify the Montelukast sodium pellets' discharge, the chrono-pharmacological requirements were met. Round and extended-release aspirin pellets have been produced utilising four different types of lipids (adeps solidus, Compritol 888 ATO, Precirol ATO5, and Compritol HD5 ATO), which were mixed in various ratios using solvent-free extrusion/spheronization. The pellets met the release requirement, according to USP.[75,76,77]

CONCLUSION:

It is clear from the overview above that selecting the right kind and quantity of excipient to use in creating pellets of the intended medicine presents the biggest problem during pellet manufacturing. Pellet characteristics are significantly impacted by water content. Changes in excipient grade, kind, or quantity have a similar impact on pellet characteristics. Distinct pelletization procedures and devices come with different obstacles. Every method and tool has advantages and disadvantages

ISSN 2515-8260 Volume 09, Issue 07, 2022

that must be considered in order to select the best method and tool for producing the desired pellets. By employing the Quality by Experimental Design technique to identify the crucial process parameters, these difficulties can be further overcome.

REFERENCE

1. Bodmeier R. Tableting of coated pellets. European journal of pharmaceutics and biopharmaceutics. 1997 Jan 1;43(1):1-8.

2. Vlosky RP. Wood-based Bioenergy: An Update for North America with a Focus on Pellets. In Proceedings of International Forestry and Environment Symposium 2016 (Vol. 21).

3. Rodríguez-Pardo D, Pigrau C, Corona PS, Almirante B. An update on surgical and antimicrobial therapy for acute periprosthetic joint infection: new challenges for the present and the future. Expert review of anti-infective therapy. 2015 Feb 1;13(2):249-65.

4. Parameswaran S, Kumar S, Verma RS, Sharma RK. Cardiomyocyte culture—An update on the in vitro cardiovascular model and future challenges. Canadian Journal of Physiology and Pharmacology. 2013;91(12):985-98.

5. Felton LA, Porter SC. An update on pharmaceutical film coating for drug delivery. Expert opinion on drug delivery. 2013 Apr 1;10(4):421-35.

6. Kaplan RM. Update on parasite control in small ruminants 2006: addressing the challenges posed by multiple-drug resistant worms. In American Association of Bovine Practitioners Conference Proceedings 2006 Sep 21 (pp. 196-206).

7. Li L, Liang T, Zhao M, Lv Y, Song Z, Sheng T, Ma F. A review on mycelial pellets as biological carriers: wastewater treatment and recovery for resource and energy. Bioresource Technology. 2022 Apr 20:127200.

8. Abdul S, Chandewar AV, Jaiswal SB. A flexible technology for modified-release drugs: multiple-unit pellet system (MUPS). Journal of controlled release. 2010 Oct 1;147(1):2-16.

9. Layek B, Mandal S. Natural polysaccharides for controlled delivery of oral therapeutics: a recent update. Carbohydrate polymers. 2020 Feb 15;230:115617.

10. Swaan J. Canbio update: Challenges for Canadian pellets. Canadian Biomass Magazine. 2009.

11. Shit SC, Shah PM. Edible polymers: challenges and opportunities. Journal of Polymers. 2014;2014.

12. Gholse YN, Yeole MP. Microencapsulation for the therapeutic delivery of Proteins and other drugs: Update and future challenges. Research Journal of Pharmacy and Technology. 2013 May 28;6(5):465-76.

13. Chamila Prageeth Pandula PK, Samaranayake LP, Jin LJ, Zhang C. Periodontal ligament stem cells: an update and perspectives. Journal of investigative and clinical dentistry. 2014 May;5(2):81-90.

14. Proskurina S, Heinimö J, Mikkilä M, Vakkilainen E. Data demonstrating the Finnish wood pellet industry and future perspectives. Data in brief. 2017 Feb 1;10:41-3.

15. Zheng Y, Wu J, Zhang L, Guo Y, Xu Z, Huang Y, Huang P, Zhang J, Zhao C. Unravelling the pore templating effect on CO2 adsorption performance of alkali metal nitrates promoted MgO pellets. Chemical Engineering Journal. 2022 Dec 15;450:137944.

16. Rodriguez Franco C. Forest biomass potential for wood pellets production in the United States of America for exportation: a review. Biofuels. 2022 Mar 29:1-2.

17. Ortega YR, Sanchez R. Update on Cyclospora cayetanensis, a food-borne and waterborne parasite. Clinical microbiology reviews. 2010 Jan;23(1):218-34.

18. Skidmore JA, Malo CM, Crichton EG, Morrell JM, Pukazhenthi BS. An update on semen collection, preservation and artificial insemination in the dromedary camel (Camelus dromedarius). Animal reproduction science. 2018 Jul 1;194:11-8.

19. Price M. Numerical simulations of the Los Alamos gapstick experiment. Bulletin of the American Physical Society. 2022 Jul 14;67.

20. Pain DJ, Fisher IJ, Thomas VG. A global update of lead poisoning in terrestrial birds from ammunition sources. Ingestion of lead from spent ammunition: implications for wildlife and humans. 2009:99-118.

21. Bansal R, Jain A, Mittal S. Current overview on challenges in regenerative endodontics. Journal of conservative dentistry: JCD. 2015 Jan;18(1):1.

22. Hamid R, Manzoor I. Nanomedicines: Nano based Drug Delivery Systems Challenges and Opportunities. Alternative Medicine-Update. 2020 Oct 30.

23. Roesch EA, Nichols DP, Chmiel JF. Inflammation in cystic fibrosis: An update. Pediatric pulmonology. 2018 Nov;53(S3):S30-50.

24. Penazzato M, Townsend CL, Rakhmanina N, Cheng Y, Archary M, Cressey TR, Kim MH, Musiime V, Turkova A, Ruel TD, Rabie H. Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list. The Lancet HIV. 2019 Sep 1;6(9):e623-31.

25. Lamers P, Mai-Moulin T, Junginger M. Challenges and opportunities for international trade in forest biomass. Mobilisation of Forest Bioenergy in the Boreal and Temperate Biomes. 2016 Jan 1:127-64.

26. Bluhm BA, Gebruk AV, Gradinger R, Hopcroft RR, Huettmann F, Kosobokova KN, Sirenko BI, Weslawski JM. Arctic marine biodiversity: an update of species richness and examples of biodiversity change. Oceanography. 2011 Sep 1;24(3):232-48.

27. Pergolizzi Jr JV, Raffa RB, Taylor Jr R, Vacalis S. Abuse-deterrent opioids: an update on current approaches and considerations. Current medical research and opinion. 2018 Apr 3;34(4):711-23.

28. Tu TZ, Liu JX, Zhou L, Liang Y, Zhang GJ. Graceful behavior during CMAS corrosion of a high-entropy rare-earth zirconate for thermal barrier coating material. Journal of the European Ceramic Society. 2022 Feb 1;42(2):649-57.
29. Moghadamnia AA. An update on toxicology of aluminum phosphide. DARU journal of Pharmaceutical Sciences. 2012 Dec;20(1):1-8.

30. Hassan SS, Williams GA, Jaiswal AK. Moving towards the second generation of lignocellulosic biorefineries in the EU: Drivers, challenges, and opportunities. Renewable and Sustainable Energy Reviews. 2019 Mar 1;101:590-9.

31. da Mata C, McKenna G, Burke FM. Caries and the older patient. Dental update. 2011 Jul 2;38(6):376-81.

32. Farmahini AH, Krishnamurthy S, Friedrich D, Brandani S, Sarkisov L. From crystal to adsorption column: challenges in multiscale computational screening of materials for adsorption separation processes. Industrial & Engineering Chemistry Research. 2018 Oct 5;57(45):15491-511.

33. Li D, Xu L, Liu H. Detection of uneaten fish food pellets in underwater images for aquaculture. Aquacultural Engineering. 2017 Aug 1;78:85-94.

34. Lutwyche PR, Challinor SF. Sellafield Decommissioning Programme-Update and Lessons Learned. British Nuclear Fuels Plc (GB); 2003 Feb 24.

35. Tang X, Yang M, Gu Y, Jiang L, Du Y, Liu J. Orally Deliverable Dual-Targeted Pellets for the Synergistic Treatment of Ulcerative Colitis. Drug Design, Development and Therapy. 2021;15:4105.

36. Bartlett CS. Clinical update: gunshot wound ballistics. Clinical Orthopaedics and Related Research®. 2003 Mar 1;408:28-57.

37. Erans M, Beisheim T, Manovic V, Jeremias M, Patchigolla K, Dieter H, Duan L, Anthony EJ. Effect of SO 2 and steam on CO 2 capture performance of biomass-templated calcium aluminate pellets. Faraday Discussions. 2016;192:97-111.

38. Wang L, Riva L, Skreiberg Ø, Khalil R, Bartocci P, Yang Q, Yang H, Wang X, Chen D, Rudolfsson M, Nielsen HK. Effect of torrefaction on properties of pellets produced from woody biomass. Energy & Fuels. 2020 Oct 23;34(12):15343-54.

39. Wright H. Outlook for wood pellets. In USIPA annual meeting, Miami Beach, FL 2014.

40. Gorman D, Moreira FT, Turra A, Fontenelle FR, Combi T, Bícego MC, de Castro Martins C. Organic contamination of beached plastic pellets in the South Atlantic: Risk assessments can benefit by considering spatial gradients. Chemosphere. 2019 May 1;223:608-15.

41. Kirby DF, Corrigan ML, Hendrickson E, Emery DM. Overview of home parenteral nutrition: an update. Nutrition in Clinical Practice. 2017 Dec;32(6):739-52.

42. Vahabi H, Laoutid F, Mehrpouya M, Saeb MR, Dubois P. Flame retardant polymer materials: An update and the future for 3D printing developments. Materials Science and Engineering: R: Reports. 2021 Apr 1;144:100604.

43. Chen LX, Clayburne G, Schumacher HR. Update on identification of pathogenic crystals in joint fluid. Current rheumatology reports. 2004 Jun;6(3):217-20.

44. Kumar V, Balasubramanian K. Progress update on failure mechanisms of advanced thermal barrier coatings: A review. Progress in Organic Coatings. 2016 Jan 1;90:54-82.

45. Stefanopoulos PK, Mikros G, Pinialidis DE, Oikonomakis IN, Tsiatis NE, Janzon B. Wound ballistics of military rifle bullets: An update on controversial issues and associated misconceptions. Journal of Trauma and Acute Care Surgery. 2019 Sep 1;87(3):690-8.

46. Pandi P, Bulusu R, Kommineni N, Khan W, Singh M. Amorphous solid dispersions: An update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed products. International journal of pharmaceutics. 2020 Aug 30;586:119560.

47. Sarabu S, Bandari S, Kallakunta VR, Tiwari R, Patil H, Repka MA. An update on the contribution of hot-melt extrusion technology to novel drug delivery in the twenty-first century: part II. Expert opinion on drug delivery. 2019 Jun 3;16(6):567-82.

48. Tasker S. Diagnosis of feline infectious peritonitis: Update on evidence supporting available tests. Journal of Feline Medicine and Surgery. 2018 Mar;20(3):228-43.

49. Yun H, Wang H, Clift R, Bi X. The role of torrefied wood pellets in the bio-economy: A case study from Western Canada. Biomass and Bioenergy. 2022 Aug 1;163:106523.

50. Maghrebi S, Prestidge CA, Joyce P. An update on polymer-lipid hybrid systems for improving oral drug delivery. Expert Opinion on Drug Delivery. 2019 May 4;16(5):507-24.

51. Buddle BM, Wedlock DN, Denis M, Vordermeier HM, Hewinson RG. Update on vaccination of cattle and wildlife populations against tuberculosis. Veterinary microbiology. 2011 Jul 5;151(1-2):14-22.

52. Bazargan A, Hadi P, Rough SL, McKay G. The preparation of pellets by the compaction of an aluminosilicate-based adsorbent from electronic waste. Journal of environmental chemical engineering. 2016 Jun 1;4(2):2322-6.

53. Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Official journal of the American College of Gastroenterology| ACG. 2011 May 1;106(5):835-42.

54. Schmid M, Beirow M, Schweitzer D, Waizmann G, Spörl R, Scheffknecht G. Product gas composition for steam-oxygen fluidized bed gasification of dried sewage sludge, straw pellets and wood pellets and the influence of limestone as bed material. Biomass and Bioenergy. 2018 Oct 1;117:71-7.

55. Jagger P, Das I. Implementation and scale-up of a biomass pellet and improved cookstove enterprise in Rwanda. Energy for Sustainable Development. 2018 Oct 1;46:32-41.

56. Kurakula M, Gorityala S, Moharir K. Recent trends in design and evaluation of chitosan-based colon targeted drug delivery systems: Update 2020. Journal of Drug Delivery Science and Technology. 2021 Aug 1;64:102579.
57. Singh D, Tiwary AK, Bedi N. Self-microemulsifying drug delivery system for problematic molecules: an update. Recent Patents on Nanotechnology. 2019 Aug 1;13(2):92-113.

58. B. Carvalho S, Peixoto C, T. Carrondo MJ, S. Silva RJ. Downstream processing for influenza vaccines and candidates: An update. Biotechnology and Bioengineering. 2021 Aug;118(8):2845-69.

59. Okewole OT, Igbeka J. Effect of some operating parameters on the performance of a pelleting press. Agricultural Engineering International: CIGR Journal. 2016 Mar 22;18(1):326-38.

60. Roccuzzo A, Stähli A, Monje A, Sculean A, Salvi GE. Peri-implantitis: a clinical update on prevalence and surgical treatment outcomes. Journal of clinical medicine. 2021 Mar 6;10(5):1107.

61. Jermain SV, Brough C, Williams III RO. Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery–an update. International journal of pharmaceutics. 2018 Jan 15;535(1-2):379-92.

62. Lam PS, Sokhansanj S, Bi X, Lim CJ, Melin S. Energy input and quality of pellets made from steam-exploded Douglas fir (Pseudotsuga menziesii). Energy & Fuels. 2011 Apr 21;25(4):1521-8.

63. Antonelou MH, Seghatchian J. Update on extracellular vesicles inside red blood cell storage units: adjust the sails closer to the new wind. Transfusion and Apheresis Science. 2016 Aug 1;55(1):92-104.

64. Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK, Webb SM, Wu FC. Testosterone replacement therapy: current trends and future directions. Human Reproduction Update. 2004 Sep;10(5):409-19.

65. Witmer G, Horak K, Moulton R, Baldwin RA. New rodenticides: an update on recent research trials.

66. McKechnie J, Saville B, MacLean HL. Steam-treated wood pellets: Environmental and financial implications relative to fossil fuels and conventional pellets for electricity generation. Applied Energy. 2016 Oct 15;180:637-49.

67. Emadi B, Iroba KL, Tabil LG. Effect of polymer plastic binder on mechanical, storage and combustion characteristics of torrefied and pelletized herbaceous biomass. Applied Energy. 2017 Jul 15;198:312-9.

68. Posom J, Shrestha A, Saechua W, Sirisomboon P. Rapid non-destructive evaluation of moisture content and higher heating value of Leucaena leucocephala pellets using near infrared spectroscopy. Energy. 2016 Jul 15;107:464-72.

69. Kowalska JD, Kazimierczak J, Sowińska PM, Wójcik EA, Siwicki AK, Dastych J. Growing trend of fighting infections in aquaculture environment—opportunities and challenges of phage therapy. Antibiotics. 2020 Jun 4;9(6):301.

70. Lee PA, Nordenström A, Houk CP, Ahmed SF, Auchus R, Baratz A, Dalke KB, Liao LM, Lin-Su K, Looijenga 3rd LH, Mazur T. Global disorders of sex development update since 2006: perceptions, approach and care. Hormone research in paediatrics. 2016;85(3):158-80.

71. Heinimö J, Junginger M. Production and trading of biomass for energy–an overview of the global status. Biomass and Bioenergy. 2009 Sep 1;33(9):1310-20.

72. Das S, Tonelli M, Ziedonis D. Update on smoking cessation: e-cigarettes, emerging tobacco products trends, and new technology-based interventions. Current psychiatry reports. 2016 May;18(5):1-5.

73. Peša I. Sawdust pellets, micro gasifying cook stoves and charcoal in urban Zambia: Understanding the value chain dynamics of improved cook stove initiatives. Sustainable Energy Technologies and Assessments. 2017 Aug 1;22:171-6.

74. Kantor CA. Design and development of an automated pellet inspection system for nuclear fuel pellets. University of Ontario Institute of Technology (Canada); 2015.
75. Bandodkar AJ, Imani S, Nunez-Flores R, Kumar R, Wang C, Mohan AV, Wang J, Mercier PP. Re-usable electrochemical glucose sensors integrated into a smartphone platform. Biosensors and Bioelectronics. 2018 Mar 15;101:181-7.

76. Lyngfelt A. Chemical looping combustion: Status and development challenges. Energy & Fuels. 2020 Jun 25;34(8):9077-93.

77. Taylor A, Barlow N, Day MP, Hill S, Patriarca M, White M. Atomic spectrometry update: review of advances in the analysis of clinical and biological materials, foods and beverages. Journal of analytical atomic spectrometry. 2017;32(3):432-76.